Avantor Opens Biorepository Facility in Europe

Modern Facility in Kriftel, near Frankfurt, Germany, Expands Geographic Reach

22.02.2021 - Avantor's investment in its new biorepository and sample archiving facility in Europe supports globalization and growing number of clinical trials, as well as rapid delivery of Covid-19 vaccines and large volumes of drugs in development.

Avantor has opened its new biorepository and sample archiving facility in Europe. Strategically located in Kriftel, near Frankfurt Airport, the new facility allows scientists to access their samples within 24 hours, for further research and analysis, or study validation.

"The number of clinical trials to support research and development (R&D) of therapeutics is rapidly increasing worldwide. The associated samples and research materials require careful handling and processing to ensure clinical trial validity" said Christophe Couturier, Executive Vice President, Services at Avantor. "The critical requirements for speed and flexibility are amplified by the Covid 19 pandemic, as well as the associated race to find safe and effective therapies - whether by testing previous discoveries or introducing new ones. Avantor can store samples at the trial end, and as vaccine production ramps up, we are able to assist producers with large volume storage.

Couturier added, "We are proud of our more than 40 years of biorepository experience, during which Avantor stored more than 100 million research commodities, and never failed to return one. This is another example of how Avantor is advancing scientific breakthroughs to create a better world."

The new Avantor biorepository and sample archiving facility in Germany has received the internationally recognized DGNB "Gold" certification for sustainable construction, which helps reduce costly risks while focusing on environmental, economic and sociocultural issues. The new facility complements the company's other facilities in Leesburg, Virginia/USA and near Nice, France.

Avantor was founded in 1904 as J.T.Baker Chemical Company and was acquired by Procter & Gamble in 1985. P&G sold the company to Mallinckrodt in 1995. 5 years later, Mallinckrodt Baker was acquired by Tyco, which subsequently renamed itself Covidien. In 2010, New Mountain Capital acquired the company from Covidien and took the Avantor-named company public in 2019 for $3.8 billion. 

With annual sales of $6.4 billion in 2020, the company now counts itself among the leading global providers of research and development products and services to customers in the biopharma, healthcare and other research industries.



One Radnor Corporate Center, Building One, Suite 200, 100 Matsonford Road
19087 Radnor
PA, United States